Boehringer posts zongertinib hepatic PK results; adds NYU-led empagliflozin dialysis trial update

Boehringer Ingelheim had several trial updates during the week, including one in a study it supports but does not lead.

• Results were posted on 2026-11-02 for a Phase 1 study of zongertinib (also known as BI 1810631 or Hernexeos) in people with hepatic impairment. The trial included people with mild liver problems, people with moderate liver problems, and people without liver problems as a matching control, to find out how mild and moderate liver impairment affect how the body processes zongertinib.¹ It enrolled 29 participants¹ and reached study completion on 2025-06-20.
• A new Phase 3 study, "AIRTIVITY®-ON" (NCT07915219), is not yet recruiting, with an estimated start of 2027-01-11. It is a roll-over study for participants who completed a previous study with verducatib: AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017).² The trial has an estimated enrollment of 1500 participants² and lists occurrence of treatment-emergent adverse events (TEAEs) over the course of this trial² as the primary outcome.
• The Phase 1 trial of BI 3034701 (NCT07708493) is completed, with primary completion on 2026-10-29. It was designed to assess the mass balance, meaning total recovery of [14C]-radioactivity in urine, faeces, and expired air, after a single subcutaneous dose of BI 3034701 (C-14) in healthy male trial participants.³ The study enrolled 8 participants³.
• A Phase 2 trial of empagliflozin in patients starting hemodialysis (NCT05786443) is listed as active, not recruiting, with its record last updated on 2026-11-06. The study is a 12-week, phase II, randomized, double-blind, placebo-controlled, multi-center study to assess the safety, tolerability, and preliminary efficacy of empagliflozin versus placebo among patients initiating hemodialysis (n=60) for the treatment of end-stage kidney disease.⁴ The trial is led by NYU Langone Health, with Boehringer Ingelheim and the National Institute of Diabetes and Digestive and Kidney Diseases listed as collaborators.